A kinder, gentler way: control of the proliferative tumor compartment, not cosmetic complete response, should be the goal of myeloma therapy
- 16 April 2008
- journal article
- Published by Springer Nature in Leukemia
- Vol. 22 (4) , 673-675
- https://doi.org/10.1038/leu.2008.2
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Suppression of abnormal karyotype predicts superior survival in multiple myelomaLeukemia, 2008
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple MyelomaCancer Cell, 2007
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du MyélomeBlood, 2007
- A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1Blood, 2006
- Complete response in myeloma: a Trojan horse?Blood, 2006
- The molecular classification of multiple myelomaBlood, 2006
- Cyclin D dysregulation: an early and unifying pathogenic event in multiple myelomaBlood, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Multiple myeloma: evolving genetic events and host interactionsNature Reviews Cancer, 2002
- A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2002